The University of Minnesota is suing Gilead Sciences Inc., alleging the Foster City-based drug company's blockbuster hepatitis C drugs infringe on a university patent.
In a lawsuit filed Monday in Minnesota's U.S. District Court, the university claimed its intellectual property covers Gilead (NASDAQ: GILD) products that contain the drug sofosbuvir, including those sold under the brand names Sovaldi and Harvoni. Those hepatitis C treatments have generated more than $20 billion in revenue for Gilead.
The...